PTC Therapeutics
PTCT
284 hedge funds and large institutions have $3.9B invested in PTC Therapeutics in 2025 Q2 according to their latest regulatory filings, with 60 funds opening new positions, 111 increasing their positions, 80 reducing their positions, and 35 closing their positions.
71% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 35
70% more call options, than puts
Call options by funds: $13.1M | Put options by funds: $7.7M
39% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 80
9% more funds holding
Funds holding: 261 → 284 (+23)
0.97% more ownership
Funds ownership: 99.87% → 100.83% (+0.97%)
3% less capital invested
Capital invested by funds: $4.02B → $3.9B (-$121M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$47.1M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$41.1M |
| 3 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$35.2M |
| 4 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
+$26.2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$25.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$76.4M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$70M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$34.4M |
| 4 |
AC
Armistice Capital
New York
|
-$33.2M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$32.8M |
PTCT Hedge Fund Activity: Q2 2025 in Review
284 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q2 2025, worth a combined $3.9B — down 3% from $4.02B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new PTCT positions and 35 closed out — a net gain of 25 holders — while 111 added to existing stakes and 80 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $47.1M. The largest seller was Camber Capital Management, exiting entirely with an estimated $76.4M sold.
- 284 institutional investors held PTC Therapeutics (PTCT) as of Q2 2025, up from 261 in Q1 2025.
- Funds reported $3.9B of PTC Therapeutics stock for Q2 2025, down 3% quarter-over-quarter.
- 60 funds opened new PTC Therapeutics positions in Q2 2025 and 35 closed out, a net change of +25 holders.
- The largest PTC Therapeutics buyer in Q2 2025 was D.E. Shaw & Co, an estimated $47.1M added.
- The largest PTC Therapeutics seller in Q2 2025 was Camber Capital Management, an estimated $76.4M sold.
Based on aggregated 13F filings for Q2 2025.